I’m running a quick poll to gauge the sequencing community’s opinion about Illumina’s proposed acquisition of PacBio. Just two simple questions. For the record, my answers are “yes” and “yes” (but I’m less confident about the second question). Check out my previous post to see my reasoning.
Specialty genomics business consulting including technical due diligence, product-market fit, competitive analysis, and technology trends.